ReviewFrontiers in pharmacology2026
Microbiota-driven metabolic-immune crosstalk in breast cancer.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer continues to pose a significant risk to women's health globally, as its progression and treatment resistance arise from an intricate interplay between metabolic reprogramming, immunological evasion, and the tumor microbiome. Augmented glycolysis has emerged as a pivotal element in cancer pathogenesis, altering the tumor microenvironment via the buildup of immune-regulated metabolites that directly influence the activation of the cGAS-STING pathway. This pathway is regarded as a significant modulator of cancer immunity, but new studies indicate that its persistent activation generally results in an immunosuppressive tumor microenvironment instead of robust antitumor immunity. Developments in multi-omics technology have revealed the therapeutic importance of the tumor microbiome, and thus, we focus on recent advancements in tumor microbiota that modify glycolytic pathways to influence the cGAS-STING signaling threshold, thereby impacting cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.